Skip to main content
ArcticZymes Technologies logo

ArcticZymes Technologies — Investor Relations & Filings

Ticker · AZT ISIN · NO0010014632 LEI · 5967007LIEEXZXGR7K47 BR Manufacturing
Open in API
Filings indexed 969 across all filing types
Latest filing 2019-04-02 Regulatory Filings
Country NO Norway
Listing BR AZT

About ArcticZymes Technologies

https://arcticzymes.com/

ArcticZymes Technologies is a life sciences company specializing in the development, manufacturing, and commercialization of novel recombinant enzymes. Leveraging over 30 years of expertise, the company discovers and engineers enzymes from cold-adapted Arctic marine organisms. These enzymes are designed to solve specific challenges in molecular applications, demonstrating high efficiency in demanding conditions such as low temperatures and high salinity. The product portfolio, including Salt Active Nucleases (SAN) and Cod Uracil-DNA Glycosylase, serves global partners in molecular diagnostics, gene therapy, vaccine production, and biomanufacturing. All products are manufactured at its ISO 13485 certified facility, ensuring high quality and performance for research and commercial use.

Recent filings

Filing Released Lang Actions
Biotec Pharmacon's subsidiary, ArcticZymes, granted ?254.000 funding from Eurostars for a synthetic biology project
Regulatory Filings Classification · 95% confidence The document is a press release dated April 2, 2019, announcing that Biotec Pharmacon's subsidiary, ArcticZymes, received funding (€254k) from the Eurostars program for a synthetic biology project involving collaboration with the University of Tromsø and Legomics. This type of announcement, detailing specific operational news, funding awards, or project updates that are not standard periodic financial reports (like 10-K or IR) or mandatory regulatory filings (like DIRS or MRQ), typically falls under general corporate news. Since it is a press release announcing a specific business development (funding/collaboration) rather than a formal regulatory filing, the most appropriate category is Regulatory Filings (RNS) as a general announcement category, or potentially Capital/Financing Update (CAP) if the funding was the primary focus, but RNS serves as the best general fit for non-standard press releases.
2019-04-02 English
Biotec Pharmacon's subsidiary, ArcticZymes, granted ?254.000 funding from Eurostars for a synthetic biology project
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Biotec Pharmacon's subsidiary, ArcticZymes, received funding from the Eurostars program for a synthetic biology project. This type of announcement, detailing specific operational news, partnerships, and funding awards, does not fit the definitions for formal financial reports (10-K, IR, ER, MRQ) or specific corporate actions (DIV, SHA, POS). It is a general corporate update. Since it is not a transcript (CT), a management discussion (MDA), or a specific regulatory filing like insider trading (DIRS) or capital change (CAP), the most appropriate classification is the general regulatory announcement/news category, which is RNS (Regulatory Filings), as it serves as a broad category for material news releases that don't fit elsewhere, or potentially LTR if it were about legal matters, but here it is about funding/collaboration. Given the nature of the announcement (grant funding and project details), RNS is the best fit as a general regulatory news release.
2019-04-02 English
Biotec Pharmacon - Mandatory notification of trade
Director's Dealing Classification · 100% confidence The document is titled 'Mandatory notification of trade' and explicitly states that an executive (CSO) has purchased shares in the company. This directly corresponds to the definition of Director's Dealing (insider trades by executives/directors). The appropriate code is DIRS.
2019-02-18 English
Biotec Pharmacon's subsidiary, ArcticZymes launches its first ligase enzyme
Regulatory Filings Classification · 95% confidence The document is a press release announcing a specific business event: the launch of a new product (T4 DNA ligase) by a subsidiary (ArcticZymes). It contains quotes from management, details about the product, and boilerplate 'About Us' sections. This type of announcement, which details operational news rather than mandatory financial reporting (like 10-K, IR, ER) or shareholder actions (like DEF 14A, DVA), typically falls under general regulatory announcements or news releases. Since there is no specific category for 'Product Launch Announcement' and it is not a formal financial report, it is best classified as a general Regulatory Filing (RNS), which serves as a broad category for official company news releases that don't fit elsewhere.
2019-02-07 English
Biotec Pharmacon's subsidiary, ArcticZymes launches its first ligase enzyme
Regulatory Filings Classification · 95% confidence The document is a short press release dated February 7, 2019, announcing that Biotec Pharmacon's subsidiary, ArcticZymes, has launched a new product (T4 DNA ligase). It contains company updates, quotes from management, and contact information. This format is characteristic of an immediate news announcement rather than a comprehensive regulatory filing (like 10-K or IR) or a formal presentation (like IP). Since it is a general announcement of a business event (product launch) that doesn't fit specific financial report codes (10-K, IR, ER, DIV, etc.), the most appropriate classification is the general regulatory announcement fallback, RNS (Regulatory Filings), as it serves as a public disclosure of material business information.
2019-02-07 English
Biotec Pharmacon awarded grant from Research Council of Norway to develop next-generation wound product
Regulatory Filings Classification · 95% confidence The document is a press release announcing that a subsidiary of Biotec Pharmacon has been awarded a significant grant from the Research Council of Norway for a 4-year R&D project related to wound care products. This type of announcement, detailing operational news, grants, or specific project updates that are not standard periodic financial reports (like 10-K, IR, ER), typically falls under general regulatory announcements or news releases. Since there is no specific category for 'Grant Award Announcement' and it is not a formal financial filing, it best fits the 'Regulatory Filings' (RNS) category, which serves as a general category for miscellaneous regulatory/corporate news that doesn't fit elsewhere. It is too specific for 'CAP' (Capital/Financing Update) as it is a grant, not debt/equity financing, and it is not a formal legal/regulatory filing like a DIRS or MRQ.
2019-02-04 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.